The changes in the above processes might influence the patient\u2019s drug recommended therapy in a number of ways. One of the ways in which it will influence it is through increasing the need for the adoption of alternative therapies that are safer for the patient. The focus<\/p>\n

of management is placed on ensuring that the therapy is tolerable by the patient and is associated with few adverse health effects. An example of this case is the prescription of drugs that are eliminated through other routes in patients with decreased renal clearance. The effect of a drug is largely dependent on the dosage of its administration. However, in the above disease states, there is a need for the re-visiting of the drug dosages to achieve optimum health effect. Therefore, rather than optimizing use of drugs in the prescribed regime, the focus shifts to minimizing the adverse outcomes with the selected plan (Rosenbaum, 2016). This includes the administration of drugs in low dosage to minimize the toxicities associated with them on the patient.<\/p>\n

One of the strategies that will be utilized to improve the drug therapy of the patient is eliminating barriers to adherence in drug use. It is important that factors contributing to non-adherence such as lack of awareness and adverse events be addressed to improve the drug therapy in a patient. For instance, the concerns of the patient related to side and adverse effects of the drugs should be addressed to enable informed decision-making. Drug therapy can also be improved by focusing on aspects that include simplifying the characteristics of the regimen, imparting knowledge, modifying the beliefs of the patient, adopting open communication, eliminating bias, and evaluating adherence (Malangu, 2018). Therefore, the use of these interventions will improve drug therapy by empowering patients to take responsibility for their health.<\/p>\n

Patient HM has a history of atrial fibrillation and a transient ischemic attack (TIA). The patient has been diagnosed with type 2 diabetes, hypertension, hyperlipidemia and ischemic heart disease. Drugs currently prescribed include the following:
\nWarfarin 5 mg daily MWF and 2.5 mg daily T, TH, Sat, Sun
\nAspirin 81 mg daily
\nMetformin 1000 mg po bid
\nGlyburide 10 mg bid
\nAtenolol 100 mg po daily
\nMotrin 200 mg 1\u20133 tablets every 6 hours as needed for pain<\/p>\n

Explain how these disease processes might influence the pharmacokinetic and pharmacodynamic processes in the patient.<\/p>\n

Describe how changes in the processes might impact the patient\u2019s recommended drug therapy.<\/p>\n

Be specific and provide examples.
\nExplain how you might improve the patient\u2019s drug therapy plan and explain why you would make these recommended improvements.<\/p>\n